Anti-cancer mechanism of hepion pharmaceuticals' crv431 highlighted in scripps research institute poster at aasld, the liver meeting® 2021

Edison, n.j., nov. 10, 2021 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and other liver diseases, today announced that results from a study conducted by dr. philippe gallay's research group at the scripps research institute examining the anti-tumor mechanism of the company's lead drug candidate, crv431, will be available as an e-poster at the liver meeting® 2021, hosted by the american association for the study of liver diseases (aasld), to be held virtually november 12-15, 2021.
HEPA Ratings Summary
HEPA Quant Ranking